Abstract
Traditional T cell therapies for solid tumors face significant challenges, including manufacturing complexity, limited efficacy of non-transduced cells, and the immunosuppressive tumor microenvironment. We present OPS-γδ, an allogeneic platform utilizing Vγ9Vδ2 γδ T cells engineered to secrete synthetic opsonins and stabilized IL-15 (stIL15). This approach leverages the innate anti-tumor properties of γδ T cells while recruiting bystander immunity through secreted payloads. Our results demonstrate that OPS-γδ cells exhibit superior cytotoxicity, persistence, and the ability to "license" unmodified cells within the therapeutic product, offering a potent, off-the-shelf solution for solid tumor immunotherapy.
Introduction: Addressing the Hurdles of Solid Tumor Immunotherapy
Current T-cell therapies, particularly chimeric antigen receptor (CAR) T cells, primarily rely on membrane-bound receptors. While successful in hematological malignancies, they face three major barriers in solid tumors:
- Manufacturing Complexity: Most CAR-T products are autologous, requiring bespoke manufacturing for each patient, which is costly and slow.
- The "Inactive Fraction": Only cells successfully expressing the transgene provide therapeutic benefit, leaving a large portion of the manufactured product as "dead weight."
- Solid Tumor Resistance: The dense, immunosuppressive environment of solid tumors often leads to T-cell exhaustion and poor penetration.
To overcome these, we developed an allogeneic (off-the-shelf) platform using γδ T cells. These cells are ideal candidates as they do not cause Graft-versus-Host Disease (GvHD) and naturally possess Antibody-Dependent Cellular Cytotoxicity (ADCC) capabilities.
Methods and Platform Design
We engineered Vγ9Vδ2 γδ T cells to serve as "micro-factories" for two key secreted payloads:
- Synthetic Opsonins (SFPs): Fusion proteins designed to bind tumor antigens (e.g., GD2) and provide an "eat me/kill me" signal via an Fc region.
- Stabilized IL-15 (stIL15): A cytokine module that enhances T-cell survival and activation without the need for exogenous supplementation.
The platform was validated across various cell lines (SupT1, Kelly) and 3D patient-derived osteosarcoma (PDOS) models. We utilized CyTOF (Mass Cytometry) and the DREVI/DREMI computational framework to analyze signaling dynamics, specifically investigating how secreted modules affect the entire cell population regardless of individual transgene expression levels.
Key Insights: The Neighborhood Effect and Bystander Recruitment
A defining feature of the OPS-γδ platform is the "Neighborhood Effect." Unlike membrane-bound CARs, secreted opsonins and IL-15 benefit the entire therapeutic batch and the surrounding environment.
- Licensing the Unmodified Fraction: Non-transduced cells (often up to 50% of a batch) are "licensed" to kill by the secreted payloads, maximizing the utility of the entire manufactured product.
- Bystander Activation: Secreted opsonins effectively "paint" tumor cells, recruiting bystander immune cells like NK cells and macrophages to participate in the attack.
- Decoupled Signaling: DREMI analysis revealed that signaling in OPS-γδ cells is uniform across the population, avoiding the "tonic signaling" and subsequent exhaustion often seen in high-expression CAR-T cells.
Key Results: Superior Cytotoxicity and Persistence
OPS-γδ cells demonstrated significantly enhanced performance compared to unmodified γδ T cells:
- Enhanced Killing: OPS-γδ cells showed potent, antigen-specific cytotoxicity against GD2+ tumor cells compared to unmodified controls.
- Superior Persistence: In mouse models, stIL15-OPS-γδ cells persisted in the blood and maintained tumor control significantly longer than unmodified cells, even without exogenous cytokine support.
- Phenotypic Optimization: Transduction triggered a shift to a CD16a+/CD16b- phenotype, the optimal configuration for potent ADCC-mediated tumor killing.
- Synergy with Zoledronic Acid: Combining OPS-γδ therapy with zoledronic acid (a common bone drug) sensitized osteosarcoma cells, further boosting efficacy in 3D models.
Limitations and Future Directions
While promising, several areas require further investigation. Primary in vivo studies were conducted in immunodeficient NSG mice; future work in humanized models is needed to fully assess the recruitment of a complete human immune system. Additionally, while we focused on GD2, the platform is modular; opsonins can be swapped to target other antigens (e.g., CD20, CEACAM5) to mitigate the risk of tumor antigen escape. Finally, achieving deep penetration into large, dense solid tumors remains a universal challenge for cellular therapy that may require additional homing modifications.
In conclusion, stIL15-OPS-γδ cells represent a novel allogeneic platform that combines direct cytolysis with bystander activation to effect solid tumor control.
Summary updated